Search
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
go.drugbank.com/conditions/DBCOND0069581Drugs: RuxolitinibSynonyms: Post ET MF, Post-ET MFApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalIt targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors [A31846]. … In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment [A31846].
Products: ERLEADA ®TABLETAS RECUBIERTAS 60 MG, ERLEADA FILM-COATED TABLET 60MGAcylcarnitine (4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine
smpdb.ca/view/SMP0123477Metabolic(4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. … form (4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine.
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreGuanfacine
go.drugbank.com/drugs/DB01018ApprovedInvestigational[L11277] Guanfacine was first described in the literature in 1974.[A189841] Guanfacine was granted FDA approval on 27 October 1986.[L11274] … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release
Products: ARİSLOW ER 1 MG UZATILMIŞ SALIMLI TABLET, 7 TABLET, ARİSLOW ER 3 MG UZATILMIŞ SALIMLI TABLET, 7 TABLETTiopronin
go.drugbank.com/drugs/DB06823ApprovedIt is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. … Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation.
Categories: N-substituted GlycinesProducts: Thiola ECFolic acid
go.drugbank.com/drugs/DB00158ApprovedInvestigationalNutraceuticalVet approvedAs a result, supplementation with 1-5mg of folic acid is recommended to prevent deficiency and a number of side effects associated with MTX therapy including mouth ulcers and gastrointestinal irritation … Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis.
Synonyms: N-pteroyl-L-glutamic acid, N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acidMixtures: Folic Acid 1mg With C 20mg, Folic Acid 1mg With Vitamin CDeflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD).
Products: DEFLAZACORT EG, CLOBAK 6 MGEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. … Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders.
Mixtures: ENOXAPARINA SODICA 40 MG JERINGAS PRELLENADASProducts: CLEXANE T, TROMBENOX TMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalIt is also a weak CYP2D6 inhibitor. FDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Products: Relistor Solution For Injection 12mg/0.6mL, RELISTOR (TM) (SUBCUTANEOUS INJECTION,12MG/0.6ML PER VIAL)